FrancophonIA/ELRC3.0 huggingface dataset:
English: Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF-antagonists, including LIFMIOR.
Croatian: Melanom i nemelanomski rak kože (engl. non-melanoma skin cancer, NMSC) primijećeni su u bolesnika liječenih antagonistima TNF-a, uključujući LIFMIOR.
English: Instead, the safety and efficacy of LIFMIOR were assessed in four randomised, double-blind, placebo-controlled studies.
Croatian: Umjesto toga djelotvornost i sigurnost primjene LIFMIORa procjenjivane su u četiri randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja.
English: The 10 mg vial is for children prescribed a dose of 10 mg or less.
Croatian: Bočica od 10 mg namijenjena je djeci kojoj je propisana doza od 10 mg ili niža.
English: Preparing the LIFMIOR dose for injection d. Adding solvent e.
Croatian: Priprema doze LIFMIOR-a za injekciju d. Dodavanje otapala e.
English: • Nervous system and eye disorders: Tell your doctor if the child has multiple sclerosis, optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of the spinal cord).
Croatian: • Poremećaji živčanog sustava i oka: obavijestite svog liječnika ako dijete boluje od multiple skleroze, optičkog neuritisa (upala vidnog živca) ili transverznog mijelitisa (oblik upale kralježničke moždine).
English: The child should not use LIFMIOR with medicines that contain the active substance anakinra or abatacept.
Croatian: Dijete ne bi smjelo primjenjivati LIFMIOR s lijekovima koji sadrže anakinru ili abatacept kao djelatnu tvar.
English: There may be a little bleeding at the injection site.
Croatian: Na mjestu davanja injekcije može nastati lagano krvarenje.
English: The primary efficacy endpoint in all four studies was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.
Croatian: Primarna mjera ishoda djelotvornosti u sva četiri ispitivanja bila je udio bolesnika u svakoj ispitivanoj skupini koji su postigli PASI 75 (tj. najmanje 75% poboljšanja u Indeksu zahvaćene površine i težine psorijaze u odnosu na početak) u 12. tjednu.
English: Patients who “failed to respond to” in the target population is defined by insufficient response (PASI<50 or PGA less than good), or worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long duration to assess response with at least each of the three major systemic therapies as available.
Croatian: Preporučena je primjena LIFMIORa u bolesnika kako je definirano u dijelu 4.1. Bolesnici koji „nisu pokazali odgovor“ u ciljnoj populaciji definirani su kao oni s nedostatnim odgovorom (PASI<50 ili PGA manji od dobar) ili pogoršanjem bolesti za vrijeme liječenja, a koji su liječeni adekvatnom dozom tijekom dovoljno dugog razdoblja da se mogao procijeniti odgovor na svaki od 3 glavna raspoloživa sistemska lijeka.
English: Approximately 15% of subjects who received LIFMIOR achieved an ACR 70 response at month 3 and month 6 compared to fewer than 5% of subjects in the placebo arm.
Croatian: Oko 15% bolesnika koji su primali LIFMIOR postiglo je odgovor ACR 70 nakon 3 ili 6 mjeseci liječenja u usporedbi s manje od 5% bolesnika koji su primali placebo.
English: • Latex: The needle cap of the MYCLIC pen is made from latex (dry natural rubber).
Croatian: • Lateks: poklopac igle napunjene brizgalice MYCLIC napravljen je od lateksa (suhe prirodne gume).
English: In a polyarticular-course juvenile idiopathic arthritis trial with LIFMIOR, 69 patients (aged 4 to 17 years) were administered 0.4 mg LIFMIOR/kg twice weekly for three months.
Croatian: U ispitivanju LIFMIORa u bolesnika s juvenilnim idiopatskim artritisom 69 bolesnika (u dobi od 4 do 17 godina) primalo je 0,4 mg LIFMIORa/kg dva puta na tjedan tijekom 3 mjeseca.
English: The known side effects of LIFMIOR include the following in groups of decreasing frequency:
Croatian: Poznate nuspojave LIFMIORa uključuju sljedeće i prikazane su slijedom prema sve manjoj učestalosti:
English: This section presents data from three studies in juvenile idiopathic arthritis, one study in paediatric patients with plaque psoriasis, four studies in adults with rheumatoid arthritis, and four studies in adults with plaque psoriasis.
Croatian: Ovaj dio prikazuje podatke iz tri ispitivanja s juvenilnim idiopatskim artritisom, jednim ispitivanjem u pedijatrijskih bolesnika s plak psorijazom, četiri ispitivanja u odraslih s reumatoidnim artritisom i četiri ispitivanja u odraslih s plak psorijazom.
English: In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with psoriasis, 9.7% of subjects with paediatric psoriasis, and 4.8% of subjects with juvenile idiopathic arthritis.
Croatian: U bolesnika liječenih odobrenim dozama etanercepta u kliničkim ispitivanjima do 12 mjeseci kumulativne stope protutijela na etanercept bile su otprilike 6% za osobe s reumatoidnim artritisom, 7,5% za osobe s psorijatičnim artritisom, 2% za osobe s ankilozantnim spondilitisom, 7% za osobe s psorijazom, 9,7% za osobe s psorijazom dječje dobi i 4,8% za osobe s juvenilnim idiopatskim artritisom.
English: If any of the following happen, do not inject more LIFMIOR.
Croatian: Ako se pojavi bilo što od sljedećeg, prestanite s ubrizgavanjem LIFMIORa.
English: In addition, in a double-blind, placebo-controlled trial in adult patients receiving background methotrexate, patients treated with LIFMIOR and anakinra were observed to have a higher rate of serious infections (7%) and neutropenia than patients treated with LIFMIOR (see sections 4.4 and 4.8).
Croatian: Osim toga, u dvostruko slijepom, placebom kontroliranom ispitivanju u odraslih bolesnika koji su primali osnovnu terapiju metotreksatom, opaženo je da su bolesnici liječeni LIFMIORom i anakinrom imali povećanu stopu ozbiljnih infekcija (7%) i neutropenije u odnosu na bolesnike liječene samo LIFMIORom (vidjeti dijelove 4.4 i 4.8).
English: Undesirable effects in adults
Croatian: Nuspojave u odraslih bolesnika
English: Non-interactions
Croatian: Izostanak interakcija
English: Powder and solvent for solution for injection (powder for injection).
Croatian: Prašak i otapalo za otopinu za injekciju (prašak za injekciju).
English: Women of childbearing potential should consider the use of appropriate contraception to avoid becoming pregnant during LIFMIOR therapy and for three weeks after discontinuation of therapy.
Croatian: Žene u reproduktivnoj dobi trebaju razmotriti korištenje odgovarajuće kontracepcije kako bi spriječile trudnoću tijekom liječenja LIFMIORom i tri tjedna nakon prestanka liječenja.
English: • Then, slowly pull the plunger back to draw the liquid into the syringe (see Diagram 11).
Croatian: • Potom polako povlačite klip van kako biste uvukli otopinu u štrcaljku (vidjeti sliku 11).
English: Do not use LIFMIOR
Croatian: Nemojte primjenjivati LIFMIOR
English: Select a clean, well-lit, flat working surface.
Croatian: Odaberite čistu, dobro osvijetljenu, ravnu radnu površinu.
English: Radiographic changes were assessed in the psoriatic arthritis study.
Croatian: U ispitivanju psorijatičkog artritisa ispitivane su radiološke promjene.
English: Before injection, LIFMIOR single-use pre-filled syringe should be allowed to reach room temperature (approximately 15 to 30 minutes).
Croatian: Prije injekcije: LIFMIOR napunjenoj štrcaljki za jednokratnu uporabu treba se dopustiti da dosegne sobnu temperaturu (približno 15 do 30 minuta).
English: Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept.
Croatian: Protutijela na etanercept otkrivena su u serumu nekih bolesnika liječenih etanerceptom.
English: A slight depression in the skin will be seen (see Diagram 4).
Croatian: Vidjet će se blago uleknuće na koži (vidjeti sliku 4).
English: • Nervous system and eye disorders: Tell your doctor if you or the child have multiple sclerosis, optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of the spinal cord).
Croatian: • Poremećaji živčanog sustava i oka: obavijestite svog liječnika ako Vi ili dijete bolujete od multiple skleroze, optičkog neuritisa (upala vidnog živca) ili transverznog mijelitisa (oblik upale kralježničke moždine).
English: • While still in the plastic package, place the vial adaptor on top of the LIFMIOR vial so that the vial adaptor spike is centered within the raised circle on top of the vial stopper (see Diagram 2).
Croatian: • Dok je nastavak za bočicu još u plastičnom pakiranju, postavite ga na vrh bočice LIFMIORa tako da šiljak nastavka za bočicu bude iznad središta odignutog kruga na gornjoj površini čepa bočice (vidjeti sliku 2).
English: LIFMIOR is supplied with pre-filled syringes containing water for injection.
Croatian: LIFMIOR se pakira s napunjenim štrcaljkama koje sadrže vodu za injekcije.
English: Infection (including upper respiratory tract infection, bronchitis, cystitis, skin infection)*
Croatian: Infekcija (uključujući infekciju gornjih dišnih puteva, bronhitis, cistitis, kožnu infekciju)*
English: Keep the pre-filled syringes in the outer carton in order to protect from light.
Croatian: Napunjene štrcaljke čuvati u vanjskom pakiranju radi zaštite od svjetlosti.
English: In studies when adult patients received concurrent treatment with LIFMIOR plus anakinra, a higher rate of serious infections compared to LIFMIOR alone was observed and 2% of patients (3/139) developed neutropenia (absolute neutrophil count < 1000/mm3).
Croatian: U ispitivanjima u kojima su odrasli bolesnici primali istodobno LIFMIOR i anakinru opažena je povećana stopa ozbiljnih infekcija u usporedbi sa samo LIFMIORom, dok je 2% bolesnika (3/139) razvilo neutropeniju (apsolutni broj neutrofila < 1000/mm
English: Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling).
Croatian: Infekcije (uključujući prehlade, upalu sinusa, bronhitis, infekcije mokraćnih putova i infekcije kože); reakcije na mjestu primjene lijeka (uključujući krvarenje, modrice, crvenilo, svrbež, bol i oticanje).
English: At 24 weeks, 56% of patients in the LIFMIOR-treated group had achieved the PASI 75 compared to 5% of placebo-treated patients.
Croatian: Nakon 24 tjedna, 56% bolesnika u skupini liječenoj LIFMIORom postiglo je PASI 75 u usporedbi s 5% u skupini koja je primala placebo.
English: For psoriatic arthritis patients with multiple joint involvement, LIFMIOR can improve your ability to do normal daily activities.
Croatian: U bolesnika sa psorijatičnim artritisom koji zahvaća više zglobova LIFMIOR može poboljšati sposobnost obavljanja uobičajenih dnevnih aktivnosti.
English: In this study, 53 patients received placebo, 214 patients received 50 mg LIFMIOR once weekly and 153 patients received 25 mg LIFMIOR twice weekly.
Croatian: U navedenom ispitivanju 53 bolesnika primalo je placebo, 214 bolesnika primalo je 50 mg LIFMIORa jednom tjedno, dok je 153 bolesnika primalo 25 mg LIFMIORa dva puta tjedno.
English: Some vaccines, such as oral polio vaccine, should not be given while using LIFMIOR.
Croatian: Neka cjepiva, kao oralno cjepivo protiv poliomijelitisa, ne bi se trebala davati za vrijeme liječenja LIFMIORom.
English: The needle cap of the pre-filled pen contains dry natural rubber (a derivative of latex).
Croatian: Pokrov za iglu napunjene brizgalice sadrži suhu prirodnu gumu (derivat lateksa).
English: There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates risk estimation.
Croatian: Postoji povećani osnovni rizik za pojavu limfoma i leukemija u bolesnika s reumatoidnim artritisom s dugotrajnom, visoko aktivnom upalnom bolešću, što otežava procjenu rizika.
English: Alternatively, 50 mg administered once weekly has been shown to be safe and effective (see section 5.1).
Croatian: Alternativno, dokazana je sigurnost primjene i djelotvornost 50 mg LIFMIORa primijenjenog jednom tjedno (vidjeti dio 5.1).
English: In part 2, 6 of 25 (24%) patients remaining on LIFMIOR experienced a disease flare compared to 20 of 26 (77%) patients receiving placebo (p=0.007).
Croatian: U drugom dijelu ispitivanja 6 od 25 (24%) bolesnika koji su ostali na LIFMIORu imalo je pogoršanje bolesti u usporedbi s 20 od 26 (77%) bolesnika koji su primali placebo (p=0,007).
English: Do NOT remove the needle cover while allowing it to reach room temperature.
Croatian: NEMOJTE uklanjati pokrov s igle dok čekate da dosegne sobnu temperaturu.
English: After 12 weeks of treatment, patients in the placebo group began treatment with blinded LIFMIOR (25 mg twice a week); patients in the active treatment groups continued to week 24 on the dose to which they were originally randomised.
Croatian: Nakon 12 tjedana liječenja bolesnici u skupini koja je primala placebo započeli su liječenje LIFMIORom na maskirani način (25 mg dva puta tjedno), a bolesnici u skupinama liječenima aktivnom terapijom nastavljali su liječenje do kraja 24. tjedna dozom na koju su od početka randomizirani.
English: At week 104, the mean change from baseline in the SPARCC score measured on MRI for all LIFMIOR-treated subjects was 4.64 for the SIJ (n=153) and 1.40 the spine (n=154).
Croatian: U 104. tjednu srednja vrijednost promjene od početne vrijednosti u SPARCC rezultatu mjerenom putem MR-a za sve LIFMIORom liječene ispitanike bila je 4,64 za sakroilijakalni zglob (n=153) i 1,40 za kralježnicu (n=154).
English: If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy, tell your doctor immediately.
Croatian: Ako se za vrijeme ili nakon terapije pojave simptomi tuberkuloze (poput stalnog kašlja, gubitka tjelesne težine, malaksalosti, blago povišene temperature) ili bilo koje druge infekcije, odmah obavijestite Vašeg liječnika.
English: Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.
Croatian: Liječenje poliartritisa (s pozitivnim ili negativnim reumatoidnim faktorom) i produljenog oligoartritisa u djece od navršene 2 godine i adolescenata u kojih postoji neadekvatan odgovor na metotreksat ili ga dokazano ne podnose.
English: Use in children and adolescents
Croatian: Primjena u djece i adolescenata
English: The long-term safety of LIFMIOR in combination with other disease-modifying antirheumatic drugs (DMARD) has not been established.
Croatian: Nije provjerena dugoročna sigurnost primjene LIFMIORa u kombinaciji s drugim antireumatskim lijekovima koji modificiraju tijek bolesti.
English: Do NOT rub the injection site.
Croatian: Nemojte trljati mjesto ubrizgavanja.
English: LIFMIOR is available in strengths of 10, 25 and 50 mg.
Croatian: LIFMIOR je dostupan u jačinama od 10, 25 i 50 mg.
English: Keep the pre-filled pens in the outer carton in order to protect from light.
Croatian: Napunjene brizgalice čuvati u vanjskom pakiranju radi zaštite od svjetlosti.
English: • Signs of nerve disorders, such as numbness or tingling, changes in vision, eye pain, or onset of weakness in an arm or leg
Croatian: • Znakovi poremećaja živaca, kao što su utrnulost ili bockanje, poremećaji vida, bol u oku, pojava slabosti ruke ili noge.
English: The double-blind period was followed by an open-label period during which all patients receive LIFMIOR 50 mg weekly for up to an additional 92 weeks.
Croatian: Nakon dvostruko slijepog razdoblja uslijedilo je otvoreno razdoblje ispitivanja tijekom kojeg su svi bolesnici primali LIFMIOR 50 mg jednom tjedno do dodatna 92 tjedna.
English: There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal outcomes (see section 4.4).
Croatian: Nakon stavljanja lijeka u promet zabilježeni su slučajevi pancitopenije i aplastične anemije, od kojih su neki imali smrtni ishod (vidjeti dio 4.4).
English: • Hold the vial firmly on the flat surface with one hand.
Croatian: • Jednom rukom čvrsto držite bočicu na ravnoj površini.
English: In part 1, all patients received 0.4 mg/kg (maximum 25 mg per dose) LIFMIOR subcutaneously twice weekly.
Croatian: U prvom dijelu ispitivanja svi su bolesnici primili 0,4 mg/kg (najviše 25 mg po dozi) LIFMIORa supkutano dva puta tjedno.
English: Radiographs of hands and wrists were obtained at baseline and months 6, 12, and 24.
Croatian: Rendgenske snimke ruku i zapešća napravljene su na početku i nakon 6, 12 i 24 mjeseca.
English: Week 12 results are shown in the table below.
Croatian: Rezultati u 12. tjednu prikazani su u tablici u nastavku.
English: Mean (SE) Annualized Change from Baseline in Total Sharp Score Placebo
Croatian: Srednja vrijednost (SE) godišnje promjene ukupnog rezultata na Sharpovoj ljestvici u odnosu na početnu vrijednost placebo etanercept
English: Please tell your doctor if you or the child in your care have a history of alcohol abuse.
Croatian: Recite svom liječniku ako Vi ili dijete o kojem skrbite imate u anamnezi alkoholizam.
English: • While holding the vial upright on the flat surface, push the plunger VERY SLOWLY until all the solvent is in the vial.
Croatian: • Držeći bočicu uspravno na ravnoj površini, IZRAZITO POLAKO potiskujte klip sve dok sva količina otapala ne bude u bočici.
English: Pyrexia
Croatian: Pireksija
English: You should consult your doctor if you become pregnant, think you may be pregnant, or are planning to have a baby.
Croatian: Ako ste trudni, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet.
English: Step 1: Preparing for an LIFMIOR injection
Croatian: Korak 1: Priprema za injekciju LIFMIORa
English: Various malignancies have also been reported with use of LIFMIOR, including cancers of the breast, lung, skin and lymph glands (lymphoma).
Croatian: Za vrijeme primjene LIFMIORa također su prijavljeni slučajevi raznih zloćudnih bolesti uključujući rak dojke, pluća, kože i limfnih žlijezda (limfomi).
English: Antibodies to LIFMIOR
Croatian: Protutijela na LIFMIOR
English: • If you have any further questions, ask your doctor, pharmacist or nurse.
Croatian: • Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili medicinskoj sestri.
English: Inspect the solution in the syringe.
Croatian: Pregledajte vizualno otopinu u štrcaljki.
English: a. p < 0.0001 compared with placebo.
Croatian: p < 0,0001 u usporedbi s placebom
English: In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been observed among patients receiving a TNF-antagonist compared with control patients.
Croatian: U kontroliranom dijelu kliničkih ispitivanja antagonista TNF-a uočeno je više slučajeva limfoma među bolesnicima koji su primali antagoniste TNF-a u usporedbi s kontrolnom skupinom bolesnika.
English: Step 4: Disposing of supplies
Croatian: Korak 4: Odlaganje uporabljenog pribora
English: If you have any questions, please talk to a doctor, nurse or pharmacist who is familiar with LIFMIOR.
Croatian: Ako imate dodatnih pitanja, molimo obratite se liječniku, medicinskoj sestri ili ljekarniku koji su upoznati s LIFMIORom.
English: Injection site reactions (including bleeding, bruising, erythema, itching, pain, swelling)*
Croatian: Reakcije na mjestu primjene injekcije (uključujući krvarenje, modrice, eritem, svrbež, bol, oticanje)*
English: One rheumatoid arthritis patient mistakenly self-administered 62 mg LIFMIOR subcutaneously twice weekly for 3 weeks without experiencing undesirable effects.
Croatian: Jedan je bolesnik greškom uzimao dozu od 62 mg LIFMIORa supkutano, dva puta tjedno tijekom 3 tjedna, bez ikakvih nuspojava.
English: During a randomised withdrawal period, significantly more patients re-randomised to placebo experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to LIFMIOR.
Croatian: Tijekom randomiziranog razdoblja prekida terapije, znatno više bolesnika koji su ponovno randomizirani u skupinu s placebom ušlo je u recidiv bolesti (gubitak odgovora PASI 75) u usporedbi s bolesnicima koji su ponovno randomizirani u skupinu s LIFMIORom.
English: Step 3: Injecting the LIFMIOR solution
Croatian: Korak 3: Ubrizgavanje otopine LIFMIORa
English: No study has been performed in patients with psoriatic arthritis using the 50 mg once weekly dosing regimen.
Croatian: Nisu provedena ispitivanja u bolesnika sa psorijatičnim artritisom pri primjeni režima doziranja od 50 mg jednom tjedno.
English: The proportion of patients treated with LIFMIOR who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients.
Croatian: Udio bolesnika liječenih LIFMIORom u kojih su se razvila protutijela na kardiolipin bio je podjednako povećan kao u bolesnika koji su primali placebo.
English: Common ≥ 1/100 to
Croatian: Rijetko ≥ 1/10 000 i
English: Withdrawing the LIFMIOR solution from the vial
Croatian: Izvlačenje otopine LIFMIORa iz bočice
English: Do not shake the pen.
Croatian: Nemojte tresti brizgalicu.
English: Abbreviation: sPGA-static Physician Global Assessment.
Croatian: b. Dermatološka statička globalna procjena (Dermatologist Static Global Assessment).
English: Patients also had plaque psoriasis with a qualifying target lesion ≥ 2 cm in diameter.
Croatian: Bolesnici su također imali plak psorijazu s kožnim promjenama promjera  2 cm.
English: Tell your doctor immediately, or go to the casualty department at your nearest hospital.
Croatian: Odmah obavijestite svog liječnika ili otiđite na odjel hitne pomoći najbliže bolnice.
English: Serious infections experienced by LIFMIOR-treated patients included cellulitis, gastroenteritis, pneumonia, cholecystitis, osteomyelitis, gastritis, appendicitis, Streptococcal fasciitis, myositis, septic shock, diverticulitis and abscess.
Croatian: U bolesnika liječenih LIFMIORom pojavile su se ozbiljne infekcije koje su uključivale celulitis, gastroenteritis, pneumoniju, kolecistitis, osteomijelitis, gastritis, apendicitis, streptokokni fasciitis, miozitis, septički šok, divertikulitis i apsces.
English: Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis including ankylosing spondylitis
Croatian: Reumatoidni artritis, psorijatični artritis i aksijalni spondioloartritis uključujući ankilozantni spondilitis
English: Patients were observed off treatment for the occurrence of rebound (PASI ≥150% of baseline) and for the time to relapse (defined as a loss of at least half of the improvement achieved between baseline and week 24).
Croatian: Bolesnici su bez liječenja praćeni s obzirom na pojavu reaktivnog pogoršanja bolesti (engl. rebound) (PASI 150% u odnosu na početni), kao i vrijeme do relapsa (definirano kao gubitak najmanje polovice poboljšanja postignutog između početka i 24. tjedna).
English: The three recommended injection sites for LIFMIOR using a pre-filled syringe include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 1).
Croatian: Tri preporučena mjesta za injekciju LIFMIOR pomoću napunjene štrcaljke uključuju: (1) prednju stranu sredine natkoljenice; (2) trbuh, s iznimkom područja u krugu 5 cm oko pupka; te (3) vanjsku stranu nadlaktice (vidjeti sliku 1).
English: Some patients have developed a reaction at an injection site that was used before.
Croatian: U nekih bolesnika pojavila se reakcija na mjestu prethodne primjene injekcije.